Killer-cell immunoglobulin-like receptor (KIR) proteins are expressed on natural killer (NK) cells and appear important in innate and adaptive immunity. There are about 14 KIR genes on chromosome 19q13.4, composed of those that inhibit and those that activate NK cell killing. Haplotypes have different combinations of these genes meaning that not all genes are present in a subject. There are two main classes of cognate human leukocyte antigen (HLA) ligands (HLA-Bw4 and HLA-C1/C2) that bind to the inhibitory/activating receptors. As a general rule, the inhibitory state is maintained except when virally infected or tumor cells are encountered; however, both increased activation and inhibition states have been associated with susceptibility and protection against numerous disease states including cancer, arthritis, and psoriasis.
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Utilizing DNA from 158 Caucasian subjects with autism and 176 KIR control subjects we show for the first time a highly significant increase in four activating KIR genes (2DS5, 3DS1, 2DS1 and 2DS4) as measured by chi square values and odds ratios. In addition, our data suggests a highly significant increase in the activating KIR gene 2DS1 and its cognate HLA-C2 ligand (2DS1 + C2; p = 0.00003 [Odds ratio = 2.87]). This information ties together two major immune gene complexes, the human leukocyte complex and the leukocyte receptor complex, and may partially explain immune abnormalities observed in many subjects with autism.
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Introduction
Autism Spectrum Disorder (ASD) is a term used for a complex group of neurodevelopmental disorders characterized by deficits in communication and social skills and the presence of restricted and repetitive stereotyped behaviors. The latest statistics released by the US Centers for Disease Control and Prevention estimate that the incidence of ASDs increased 23% from 2006 to 2008 to 1 in 88 children (CDC, 2012) .
Years ago familial clustering and twin studies indicated a strong genetic component to predisposition; however, after extensive genetic research, only a small number of cases can be associated with specific genes (McClellan and King, 2010) . There is considerable evidence that suggests involvement of the immune system in the etiology of autism (Westover et al., 2011) .
Both cellular and humoral immunological changes have been reported in children with autism. Those abnormalities include changes in certain immune cell functions (Ashwood et al., 2010) , an increase in the C4B null allele (Warren et al., 1991; Odell et al., 2005; Mostafa and Shehab, 2010) , association of certain human leukocyte antigen (HLA) alleles (Torres et al., 2002 (Torres et al., , 2006 , and an increase in certain ancestral HLA haplotypes (Daniels et al., 1995) . These last three papers, published by our research group, have all described typical HLA Class I and Class II HLA antigen-presenting alleles which involve different protein binding sites (T-cell receptor) outside the KIR binding sites. Additional immune associations include imbalances in antibody levels (Croonenberghs et al., 2002; Heuer et al., 2008; Enstrom et al., 2009b) , an increase in autoantibodies to neural tissue (Cabanlit et al., 2007; Wills et al., 2009; Rosenspire et al., 2011) , altered cytokine levels (Molloy et al., 2006; Ashwood et al., 2011) , changes in lymphocyte subsets (Furlano et al., 2001 ), a family history of autoimmune diseases (Atladóttir et al., 2009) , and reduced natural killer (NK) cell activity (Warren et al., 1987; Enstrom et al., 2009a) .
